Keyphrases
Polymorphism
100%
Acute Lymphoblastic Leukemia
100%
Maintenance Treatment
100%
Maintenance Phase
100%
Reduced Toxicity
100%
Pharmacogenomics
100%
Pediatric Acute Lymphoblastic Leukemia
66%
Methotrexate
66%
Leukemia Therapy
66%
6-mercaptopurine (6-MP)
66%
Drug Use
33%
Ethnic Groups
33%
Life-threatening
33%
Family Members
33%
Relapse Risk
33%
Organic Anion Transporter
33%
Methylenetetrahydrofolate Reductase (MTHFR)
33%
Myelosuppression
33%
Number of children
33%
SLCO1B1
33%
Gastrointestinal Toxicity
33%
Effective Predictor
33%
Chemotherapy Treatment
33%
Solute Carrier Family
33%
SLC19A1
33%
Solute Carrier
33%
Transporter Family
33%
Inosine Triphosphatase
33%
Nudix Hydrolase 15
33%
NUDT15
33%
Thymidylate Synthetase
33%
Thiopurine Methyltransferase
33%
Methotrexate Toxicity
33%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacogenomics
100%
Acute Lymphoblastic Leukemia
100%
Methotrexate
75%
Mercaptopurine
50%
Chemotherapy
25%
SLCO1B1
25%
Thymidylate Synthase
25%
Gastrointestinal Toxicity
25%
Nudix Hydrolase
25%
Thiopurine Methyltransferase
25%
Solute Carrier Organic Anion Transporter 1B1
25%
Reduced Folate Carrier
25%
Dihydrofolate Reductase
25%
Bone Marrow Suppression
25%
Inosine
25%
Biochemistry, Genetics and Molecular Biology
Mercaptopurine
66%
Nudix Hydrolase
33%
Inosine Triphosphatase
33%